Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system

被引:37
作者
Sun, Xiangyu [1 ]
Zhao, Ping [2 ]
Lin, Jierou [2 ]
Chen, Kun [3 ,6 ]
Shen, Jianliang [4 ,5 ,7 ]
机构
[1] Beijing Chaoyang Emergency Med Rescuing Ctr, Med & Equipment Dept, Beijing 100026, Peoples R China
[2] Guangdong Pharmaceut Univ, Educ Meg Ctr, Sch Chem & Chem Engn, Guangzhou 510006, Guangdong, Peoples R China
[3] Beijing Chaoyang Emergency Med Rescuing Ctr, Beijing 100026, Peoples R China
[4] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Sch Biomed Engn, Wenzhou 325035, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Wenzhou Inst, Wenzhou 325001, Zhejiang, Peoples R China
[6] Beijing Chaoyang Emergency Med Rescuing Ctr, 1 Southern Branch Tianshuiyuan Dongli, Beijing 100026, Peoples R China
[7] Wenzhou Med Univ, Sch Ophthalmol & Optometry, Sch Biomed Engn, 270 Xueyuan West Rd, Wenzhou 325035, Zhejiang, Peoples R China
关键词
Cancer; nanomedicine; nanomaterials; drug delivery; multidrug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; P-GLYCOPROTEIN INHIBITORS; HUMAN SERUM-ALBUMIN; CELL LUNG-CANCER; MULTIDRUG-RESISTANCE; PHASE-I; MOLECULAR-MECHANISMS; CO-DELIVERY; DNA-DAMAGE; NANOPARTICLES;
D O I
10.20517/cdr.2023.16
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer is currently one of the most intractable diseases causing human death. Although the prognosis of tumor patients has been improved to a certain extent through various modern treatment methods, multidrug resistance (MDR) of tumor cells is still a major problem leading to clinical treatment failure. Chemotherapy resistance refers to the resistance of tumor cells and/or tissues to a drug, usually inherent or developed during treatment. Therefore, an urgent need to research the ideal drug delivery system to overcome the shortcoming of traditional chemotherapy. The rapid development of nanotechnology has brought us new enlightenments to solve this problem. The novel nanocarrier provides a considerably effective treatment to overcome the limitations of chemotherapy or other drugs resulting from systemic side effects such as resistance, high toxicity, lack of targeting, and off-target. Herein, we introduce several tumor MDR mechanisms and discuss novel nanoparticle technology applied to surmount cancer drug resistance. Nanomaterials contain liposomes, polymer conjugates, micelles, dendrimers, carbon-based, metal nanoparticles, and nucleotides which can be used to deliver chemotherapeutic drugs, photosensitizers, and small interfering RNA (siRNA). This review aims to elucidate the advantages of nanomedicine in overcoming cancer drug resistance and discuss the latest developments.
引用
收藏
页码:390 / 415
页数:26
相关论文
共 206 条
[1]   P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review [J].
Abdallah, Hossam M. ;
Al-Abd, Ahmed M. ;
El-Dine, Riham Salah ;
El-Halawany, Ali M. .
JOURNAL OF ADVANCED RESEARCH, 2015, 6 (01) :45-62
[2]   A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer [J].
Ahn, Hee Kyung ;
Jung, Minkyu ;
Sym, Sun Jin ;
Shin, Dong Bok ;
Kang, Shin Myung ;
Kyung, Sun Young ;
Park, Jeong-Woong ;
Jeong, Sung Hwan ;
Cho, Eun Kyung .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (02) :277-282
[3]   The biochemical and molecular mechanisms involved in the role of tumor micro-environment stress in development of drug resistance [J].
Al-Akra, Lina ;
Bae, Dong-Hun ;
Leck, Lionel Y. W. ;
Richardson, Des R. ;
Jansson, Patric J. .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2019, 1863 (09) :1390-1397
[4]   Nonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption [J].
Al-Ali, Ahmed A. Abdulhussein ;
Nielsen, Rasmus Blaaholm ;
Steffansen, Bente ;
Holm, Rene ;
Nielsen, Carsten Uhd .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 566 :410-433
[5]   Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery [J].
Almeida, Bethany ;
Nag, Okhil K. ;
Rogers, Katherine E. ;
Delehanty, James B. .
MOLECULES, 2020, 25 (23)
[6]   ABC Transporter-Mediated Multidrug-Resistant Cancer [J].
Amawi, Haneen ;
Sim, Hong-May ;
Tiwari, Amit K. ;
Ambudkar, Suresh V. ;
Shukla, Suneet .
DRUG TRANSPORTERS IN DRUG DISPOSITION, EFFECTS AND TOXICITY, 2019, 1141 :549-580
[7]   Adaptive evolution reveals a tradeoff between growth rate and oxidative stress during naphthoquinone-based aerobic respiration [J].
Anand, Amitesh ;
Chen, Ke ;
Yang, Laurence ;
Sastry, Anand V. ;
Olson, Connor A. ;
Poudel, Saugat ;
Seif, Yara ;
Hefner, Ying ;
Phaneuf, Patrick V. ;
Xu, Sibei ;
Szubin, Richard ;
Feist, Adam M. ;
Palsson, Bernhard O. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (50) :25287-25292
[8]  
[Anonymous], WHO report on cancer: setting priorities, investing wisely and providing care for all
[9]   Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J].
Arnold, CN ;
Goel, A ;
Boland, CR .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :66-73
[10]   Drug Resistance in Cancer Therapy and the Role of Epigenetics [J].
Asano, Takeshi .
JOURNAL OF NIPPON MEDICAL SCHOOL, 2020, 87 (05) :244-251